Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Both agents provided clinically meaningful reductions in HbA 1c (2.6 mmol/mol [0.2%] with SGLT2i and 5.4 mmol/mol [0.5%] with GLP-1 RA)
Likewise, HbA1c levels may stop declining even though the patient continues therapy
Indicators of high risk include being 55 years of age or older with coronary, carotid, or lower extremity artery stenosis of more than 50% or with left ventricular hypertrophy
I'm on week six of the 0.25 dose because it's enough for me, and I don't see a reason to increase the dose
N.FritzK.ParmarM
Were living in a digital-first era
US$ 22.74
US$ 25.87
![In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
![Tirzepatide vs. Semaglutide: Which Weight Loss Drug Works Better? [May 2025 NEJM Study Explained]](https://belite.com/wp-content/uploads/2025/06/July-2025-Blog-Post-Belite.png)
US$ 25.73
![Knight (002/016) [Dominaria Tokens] SPA Vampiro voraz](https://cdn.shopify.com/s/files/1/0268/5285/1798/products/2516852e-166f-51a8-a679-4365fc2eab10.jpg?v=1638303113)
